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Editor: D. BarceloThe distribution of micropollutants in biotic phases of horizontal sub-surface flow (HSSF) constructed wetlands
was investigated. 88 diverse micropollutants (personal care products, pharmaceuticals and illicit drugs) were
monitored for in full-scale HSSF steel slag and gravel beds to assess their fate and behaviour during tertiary
wastewater treatment. Of the studied micropollutants 54 were found in receiving and treated wastewaters.
Treatment reduced concentrations of several micropollutants by N50% (removal range−112% to 98%) and re-
sulted in changes to the stereo-isomeric composition of chiral species. For example, stereo-selective changes
were observed for 3,4-methylenedioxymethamphetamine (MDMA) and atenolol during HSSF constructed wet-
land treatment for the first time. Analysis of sludge present within the HSSF beds found 37micropollutants to be
present. However, concentrations for the majority of these micropollutants were not considered high enough to
suggest partitioning into sludge was a contributing mechanism of removal. Nevertheless the preservative
methylparaben was found at 2772 mg bed−1. Its daily removal from wastewater of 3.4 mg d−1 indicates
partitioning and accumulation in sludge contributes to its removal. Other micropollutants found at high levels
in sludge (relative to their overall removals) were the antidepressants sertraline and fluoxetine, and the metab-
olite desmethylcitalopram. Furthermore, process balances indicated uptake and metabolism by Phragmites
australis (Cav.) Trin. ex Steud did not contribute significantly to micropollutant removal. However analysis of
plant tissues evidenced uptake, metabolism and accumulation of recalcitrant micropollutants such as ketamine
and carbamazepine. It is considered that the rate of uptake was too slow to have a notable impact on removalKeywords:
Micropollutant
Pharmaceutical
Wastewater
Reeds
Chiral
Plantniversity of Bath, Bath BA2 7AY, UK.
sprzyk-Hordern).
649B. Petrie et al. / Science of the Total Environment 630 (2018) 648–657at the 14h hydraulic retention time.Despite evidence of other removalmechanisms at play (e.g., partitioning into
sludge and plant uptake), findings indicate biodegradation is the dominant mechanism of micropollutant re-
moval in HSSF constructed wetlands.
© 2018 Published by Elsevier B.V.1. Introduction
Constructed wetlands are being used as a tertiary treatment option
for secondary effluent polishing to meet increasingly stringent dis-
charge limits. Horizontal sub-surface flow (HSSF) is a popular wetland
configuration in which water flows through a porous medium or sub-
strate such as gravel (Verlicchi and Zambello 2014). These systems
tend to be planted with macrophytes such as Phragmites australis (the
common reed). They are primarily used for the removal of conventional
pollutants including suspended solids, nutrients and bulk organic mat-
ter (Verlicchi and Zambello 2014). However, fortuitous removals of
other pollutants such as pharmaceuticals have been observed in several
studies (Verlicchi and Zambello 2014; Ávila et al. 2015;Matamoros et al.
2016).
To date, the majority of studies focused onmicropollutants measure
their net removal during HSSF constructed wetland treatment (i.e., de-
terminemicropollutant concentrations before and after treatment only)
(Verlicchi and Zambello 2014). However, to better appreciate
micropollutant fate and behaviour it is essential to determine their dis-
tribution between the various biotic phases of the process. For example
the build up of sludge within the wetland bed can act as sink for the ac-
cumulation of micropollutants. Furthermore, there is a paucity of infor-
mation on micropollutant uptake by P. australis under field conditions.
The presence of plants is known to improve micropollutant removal in
constructed wetlands (Hijosa-Valsero et al., 2010; Matamoros et al.
2012). For example,Matamoros et al. (2012) found removals of caffeine
and ibuprofen were 40–80% inmicrocosm studies with plants, whereas
in equivalent reactors without plants the removalwas 2–30%. Plants are
known to take up and assimilate nutrients, act as a surface for biofilm
growth, pump and release O2, retain suspended particles and insulate
against low temperatures (Tanner 2001; Kyambadde et al. 2004). Previ-
ous studies have provided evidence of micropollutant uptake and me-
tabolism by plants in controlled experiments (He et al. 2017; Lv et al.
2017). He et al. (2017) proposed that following uptake by P. australis,
ibuprofen is catalyzed by cytochrome P450mono oxygenase and glyco-
syltransferase. Further storage or metabolism was then mediated in
vacuoles or cell walls. However, it is unknown if uptake andmetabolism
by plants directly plays a significant role on overall micropollutant re-
movals in full-scale systems. Overall there has been little analysis un-
dertaken on solid matrices of HSSF constructed wetlands (e.g., sludge
and plant tissues). The lack of analysis is due to the lack of good analyt-
ical approaches available as well as the further sample preparation re-
quirements (Petrie et al. 2015).
Despite ~50% of pharmaceuticals being chiral and likely to undergo
stereo-selective changes during HSSF wetland treatment, the majority
of previous studies have not considered this when assessing
micropollutants removal. This is essential to monitor as stereo-specific
toxicity is known to occur in the environment (Stanley et al. 2006;
Stanley et al. 2007; DeAndrés et al. 2009). Nevertheless, very little infor-
mation is available in the literature on the stereo-selective transforma-
tion of chiral micropollutants by HSSF constructed wetlands. Only
ibuprofen and naproxen have been studied in any detail previously,
and have shown to undergo stereo-selective degradation (Matamoros
et al. 2009; Hijosa-Valsero et al. 2010).
To further our understanding of HSSF constructed wetlands for
micropollutant remediation, the aim of this study was to examine the
(stereo-selective) distribution of chiral and achiral micropollutants be-
tween different biotic phases of constructed wetlands. This wasachieved by studying three differently configured HSSF wetlands:
steel slag bed operated for 2 months, gravel bed operated for 2 months
and gravel bed operated for 12 months. These were all planted with P.
australis and treated the same wastewater. A total of 88 chemically
and biologically diverse chiral and achiral micropollutants were studied
(see Table S1, Supplementary material). Receiving wastewater (trick-
ling filter effluent), constructed wetland effluent, sludge and P. australis
were analysed for the full suite of micropollutants.
2. Materials and methods
2.1. Materials
All materials used in the investigation are described in the Supple-
mentary material. This includes all analytical reference standards and
reagents for mobile phase preparation and sample extraction. The pro-
cedure for deactivating glassware is also described here.
2.2. Analytical methods
2.2.1. Liquid matrices
Liquid wastewater samples were filtered (GF/F filters, 0.7 μm) and
50 mL aliquots spiked with 50 ng of all internal standards. Samples
were loaded onto Oasis HLB SPE cartridges pre-conditioned using
2 mL methanol (MeOH) followed by 2 mL H2O. Samples were loaded
at 5 mL min−1 then dried under vacuum. Analytes were then eluted
using 4 mL MeOH at a flow rate of 1 mL min−1. Extracts were dried
under nitrogen using a TurboVap evaporator (Caliper, UK, 40 °C, N2,
b5 psi) and reconstituted in 500 μL 80:20 H2O:MeOH (Waters, Man-
chester, UK) ready for UHPLC-MS/MS analysis (Petrie et al. 2016).
2.2.2. Phragmites australis
Plants were frozen and freeze dried (ScanVac, CoolSafe freeze dryer,
Lynge, Denmark) prior to extraction. Samples were then homogenized
using a mechanical blender (Kenwood, Havant, UK). Representative
0.5 g samples were spiked with 50 ng of all internal standards (in 50
μL MeOH) and left for a minimum of 2 h. Extraction was performed
using 25 mL of 25:75 MeOH:H2O at a temperature of 50 °C using a
800 W MARS 6 microwave (CEM, UK). Once cooled to room tempera-
ture, sampleswere dilutedwithH2O to achieve a finalMeOH concentra-
tion of b5%, and treated as a liquid sample as in Section 2.2.1.
Reconstituted samples were filtered through pre-LCMS 0.2 μm PTFE fil-
ters (Whatman, Puradisc) (Petrie et al. 2017). A single plantwas also di-
vided into different sections (roots, leaves and 4 × 30 cm section of
stem) to investigate within-plant micropollutant distribution. Each sec-
tion of plant was treated as described previously.
2.2.3. Sludge
Sludge was frozen and freeze dried (ScanVac). 0.5 g samples were
spiked with 50 ng of all internal standards and left for a minimum of
2 h. These were then extracted with 25 mL 50:50 MeOH:H2O (pH 2)
at 110 °C using a 800 W MARS 6 microwave (CEM). Sample extracts
were then adjusted to b5% MeOH using H2O (pH 2) and filtered (0.7
μm). SPE was then performed using Oasis MCX cartridges conditioned
with 2 mL MeOH and 2 mL H2O (pH 2). Samples were loaded at
5 mL min−1 and dried. Analytes were eluted in separate fractions to re-
duce matrix interferences from the high complexity of sludge extracts
using 0.6% HCOOH in MeOH and 7% NH4OH in MeOH (fraction 2).
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and filtered through pre-LCMS 0.2 μm PTFE filters (Whatman) (Petrie
et al. 2016).
2.2.4. LC-MS/MS analysis
To determine micropollutant concentrations, 2 chromatography
methods were used. Acidic analytes were separated using a gradient
of 1 mM NH4F in 80:20 H2O:MeOH (mobile phase A) and 1 mM NH4F
in 5:95 H2O:MeOH (mobile phase B). Initial conditions of 100% A were
maintained for 0.5 min before reducing to 40% over 2 min and further
reduced to 0% over 5.5 min. Separation of basic analytes was performed
using 5 mMNH4OAc and 3 mMCH3COOH in 80:20 H2O:MeOH (mobile
phase A) and MeOH (mobile phase B). Starting conditions of 100% A
were reduced to 10% over 20 min and maintained for a further 6 min.
Both methods utilised a reversed-phase BEH C18 column (150
× 1.0 mm, 1.7 μm particle size) (Waters, Manchester, UK) maintained
at 40 °C using a Waters Acquity UPLC system (Waters). The mobile
phase flow rate was 0.04 mL min−1 and an injection volume of 15 μL
used for both methods (Petrie et al. 2016).
To determine the enantiomeric fraction (EF) of chiral
micropollutants, analytes were separated using a Cellobiohydrolase col-
umn (100 × 2mm, 5 μmparticle size) (Chiral Technologies, France) and
a mobile phase consisting 1 mM NH4OAc in 85:15 H2O:MeOH. Separa-
tion was achieved under isocratic conditions with a mobile phase flow
rate of 0.1 mL min−1. Here the injection volume was 20 μL
(Castrignanò et al. 2016). EFs were calculated according to Eq. (1):
EF ¼ þð Þþð Þ þ −ð Þ½  ð1Þ
where (+) is the peak area of the (+)-enantiomer or the first eluting
enantiomer if the elution order is not known, corrected for the deuter-
ated internal standard response and (−) is the peak area of the (−)-en-
antiomer or the second eluting enantiomer corrected for the deuterated
internal standard response.
In all methods the LC system was coupled to a Xevo TQD Triple
Quadrupole Mass Spectrometer (Waters), equipped with an
electrospray ionisation (ESI) source. Acidic analytes were analysed in
negative ionisation mode (ESI−) with a capillary voltage of 3.20 kV.
Basic micropollutants were analysed in positive ionisation mode (ESI
+)with a capillary voltage of 3.00 kV. The optimisedMS/MS transitions
can be found in Table S2 (See Supplementarymaterial). The source tem-
perature was 150 °C whilst the desolvation temperature was 400 °C. A
cone gas flow of 100 L h−1and a desolvation gas flow of 550 L h−1
was used. Finally, the nebulising and desolvation gases were nitrogen,
and the collision gas was argon (Petrie et al. 2016). For validation infor-
mation of all methods please see Table S3 (See Supplementary
material).
2.3. Constructed wetlands
All samples were collected from a wastewater treatment plant
(WTP) which serves a population equivalent of 12,500 located in the
South-West of the UK (average dry weather flow = 1850 m3 d−1). It
consists of primary sedimentation, secondary treatment by trickling fil-
ters and sedimentation followed by constructed wetlands as a final
polishing step. The constructed wetlands consist of three different
beds (in duplicate) configured with identical dimensions (55 × 10 m)
treating the samewastewater. They operated as non-aerated HSSF wet-
lands with differing substrates planted with P. australis (planting den-
sity = 4–6 plants per m2). One bed had a steel slag substrate (40.0%
CaO, 28.5% Fe2O3, 11.2% SiO2, 9.7% MgO, 3.4% Al2O3, 2.5% Mn3O4, 1.3%
P2O5 and b1.0% TiO2, Cr2O3, V2O5, Na2O, K2O, BaO and SO3) whilst the
others were siliceous gravel. The depth of substrate was approximately
1 m and flow was controlled to achieve an estimated hydraulic reten-
tion time (HRT) of 14 ± 2 h. One gravel bed was considered well-established as it had been operating for 12 months and P. australis
were generally 1.5 to 2.0 m in height. In the remaining beds P. australis
were planted 2 months prior to sampling and were ~0.5 m in height
(See Fig. S1, Supplementary material). Samples were collected from
the inlet of the constructed wetlands as well as final effluent from
each differently configured bed (see Figs. S2 and S3, Supplementaryma-
terial). 24 h time proportional composite samples (80mL every 15min)
were collected and cooled to 4 °C. Micropollutant removals (%) were
calculated by taking account of their difference in concentration be-
tween the inlet and final effluent for each differently configured bed.
Sludge/sediment (~10 g) was extracted from the top 10 cm of the sub-
strate bed, and whole plants (including roots) were collected from
near the inlet and outlet of the gravel bed which had been in operation
for 12 months on each sampling day (see Fig. S3, Supplementary mate-
rial). Both plants and sludge samples were collected in duplicate from
each sampling point. Roots were rinsed under tap water to remove ex-
cess sludge. All samples were transported to the laboratory on ice and
within 30 min of collection. Sampling was performed during four con-
secutive days in July 2015.
2.4. Microcosm studies
Microcosm studies were prepared to examine mechanisms of re-
moval. Microcosms were prepared in autoclaved 2 L Erlenmeyer flasks
and filled with steel slag substrate collected from the constructed wet-
land, accounting for ~50% of the flask volume (see Fig. S3, Supplemen-
tary material). Substrate was collected at a depth of N5 cm to ensure
the presence of a biofilm. Flasks were then filled with 1 L of trickling fil-
ter effluent (collected as a grab sample during July 2015). Prepared mi-
crocosms were treated to achieve the following conditions; (i) dark
biotic - A, (ii) dark abiotic - B, (iii) light biotic - C, (iv) light abiotic - D,
(v) light biotic (no substrate) - E, and (vi) light abiotic (no substrate) -
F. “Light” microcosms were left exposed to ambient light in the labora-
tory (windows and overhead lighting) whereas the “dark”microcosms
were wrapped in aluminium foil. The effluent in abiotic microcosms
was treated with 1 g L−1 NaN3 to inhibit biological activity. Sterile cot-
ton wool plugs were used to seal each microcosm. Samples were col-
lected at times 0, 4, 22, 26, 46 and 50 h.
3. Results and discussion
3.1. Micropollutants in liquid matrices of HSSF constructed wetlands and
their speciation
A total of 88 micropollutants were monitored including a range of
pharmaceutical drug sub-classes (e.g., antibiotics, anti-hypertensives,
lipid regulators, anti-histamines, diabetes, beta-blockers, H2 receptor
agonists, anaesthetics, anti-depressants, analgaesics and anti-epilep-
tics), personal care products (UV filters, parabens), steroid estrogens,
the plasticizer bisphenol-A, licit stimulants and illicit drugs (stimulants
and opioids), as well as metabolites. In receiving wastewater for treat-
ment (trickling filter effluent) 54 micropollutants were present, with
all major micropollutant classes and sub-classes represented (Table 1).
Concentrations ranged from ng L−1 to the low μg L−1 range and were
representative of previously reported levels in municipal effluents
(Petrie et al. 2015). The micropollutant found at the highest average
concentration was the UV filter benzophenone-4 at 4164 ± 119 ng L−
1 (Table 1).
Novel bed substrates such as steel slag have been proposed as an al-
ternative bed substrate in HSSF constructed wetlands to enhance phos-
phorus removals (Ge et al. 2016; Park et al. 2016). However, there is a
paucity of information on steel slag for micropollutant remediation.
Under field conditions (operational for 2 months), the steel slag HSSF
constructed wetland was successful at removing some micropollutants
by N50% (Table 2). This included licit stimulants (caffeine, nicotine and
cotinine), non-steroidal anti-inflammatory drugs (NSAIDs, ibuprofen,
Table 1
Micropollutant concentrations determined in inlet trickling filter effluent, final effluent from the 3 differently configured beds, sludge and P. australis.
Micropollutant class Micropollutant Inlet – trickling
filter effluent
(ng L−1)
Final effluent Sludge (μg
kg−1 dry
weight)
P. australis
(μg kg−1 dry
weight)
Steel slag substrate
– 2 months
(ng L−1)
Gravel substrate – 2
months
(ng L−1)
Gravel substrate –
12 months
(ng L−1)
UV filters Benzophenone-1 bMQL bMQL bMQL bMQL 6.4 ± 2.1 bMQL
Benzophenone-2 bMQL bMQL bMQL bMQL bMQL bMQL
Benzophenone-3 46.0 ± 7.3 64.6 ± 19.3 31.1 ± 2.8 69.6 ± 17.9 – bMQL
Benzophenone-4 4164 ± 118.6 3803 ± 394.2 3858 ± 89.8 3719 ± 222.6 bMQL bMQL
Parabens Methylparaben 23.8 ± 1.8 22.6 ± 4.1 19.9 ± 1.6 19.8 ± 2.7 308 ± 119 197 ± 83.8
Ethylparaben bMQL bMQL bMQL bMQL bMQL bMQL
Propylparaben 6.1 ± 0.6 7.5 ± 2.1 6.0 ± 0.7 8.6 ± 2.0 2.7 ± 0.4 bMQL
Butylparaben bMQL bMQL bMQL bMQL bMQL bMQL
Plasticizer Bisphenol-A 245 ± 150.2 242 ± 218.0 166 ± 20.3 184 ± 40.2 356 ± 187 78.4 ± 43.4
Steroid estrogens E1 26.0 ± 10.4 16.0 ± 4.3 bMQL bMQL bMQL bMQL
E2 bMQL bMQL bMQL bMQL bMQL bMQL
EE2 bMQL bMQL bMQL bMQL – bMQL
Human
antibiotics/antibacterials
Sulfasalazine 386 ± 35.2 392 ± 24.5 282 ± 39.1 173 ± 6.8 – bMQL
Clarithromycin 572 ± 121.9 152 ± 24.8 311 ± 48.4 301 ± 27.2 – bMQL
Azithromycin bMQL bMQL bMQL bMQL – bMQL
Trimethoprim 646 ± 105 483 ± 42.3 353 ± 33.5 213 ± 41.4 48.4 ± 28.3 bMQL
Sulfamethoxazole 46.8 ± 7.0 37.8 ± 9.3 33.3 ± 4.3 32.8 ± 4.2 2.5 ± 0.3 bMQL
Triclosan 129 ± 16.3 129 ± 24.8 104 ± 15.3 102 ± 8.2 – –
Antihypertensives Valsartan 415 ± 72.9 336 ± 35.6 345 ± 37.8 323 ± 20.2 – bMQL
Irbesartan 667 ± 70.7 644 ± 84.2 701 ± 77.7 695 ± 71.4 – bMQL
Lisinopril 149 ± 41.7 55.5 ± 10.7 bMQL bMQL bMQL –
NSAIDs Ketoprofen bMQL bMQL bMQL bMQL bMQL bMQL
Ibuprofen 432 ± 25.3 314 ± 51.9 317 ± 32.3 300 ± 47.9 17.3 ± 5.0 bMQL
Naproxen 1497 ± 165 1146 ± 217.7 1152 ± 74.4 1013 ± 139 34.0 ± 17.9 bMQL
Diclofenac 2099 ± 1224 1770 ± 851.0 1639 ± 568 1691 ± 594 39.0 ± 11.2 bMQL
Acetaminophen 273 ± 158.5 152 ± 144.4 70.9 ± 18.7 95.1 ± 25.4 bMQL bMQL
Lipid regulators Bezafibrate 969 ± 23.5 520 ± 40.2 509 ± 30.6 383 ± 51.0 bMQL bMQL
Atorvastatin 418 ± 142 273 ± 55.4 139 ± 27.8 132 ± 8.4 – bMQL
Antihistamines Fexofenadine 1922 ± 111 1668 ± 29.7 1190 ± 143.4 664.0 ± 66.5 – bMQL
Cetirizine 650 ± 63.0 610 ± 57.5 588 ± 72.0 572 ± 70.8 – bMQL
Diabetes Gliclazide 83.8 ± 10.7 63.9 ± 13.6 71.0 ± 5.8 71.8 ± 1.8 – bMQL
Cough suppressant Pholcodine bMQL bMQL bMQL bMQL bMQL bMQL
Beta-blocker Atenolol 287 ± 27.6 89.1 ± 7.7 61.1 ± 7.4 64.5 ± 7.4 4.6 ± 0.4 bMQL
Metoprolol 4.9 ± 3.4 4.0 ± 1.7 3.5 ± 1.4 2.9 ± 1.5 1.3 ± 1.0 bMQL
Propranolol 132 ± 3.5 107 ± 5.7 110 ± 5.3 92.3 ± 3.3 120 ± 35.5 29.1 ± 25.1
H2 receptor agonists Ranitidine 1335 ± 123.1 1005 ± 75.4 889 ± 62.1 755 ± 88.0 313 ± 157 bMQL
Cimetidine bMQL bMQL bMQL bMQL – bMQL
X-ray contrast media Iopromide bMQL bMQL bMQL bMQL – bMQL
Drug precursor and
metabolite
Ephedrine/pseudoephedrine 78.0 ± 8.5 62.2 ± 5.5 33.1 ± 7.3 24.0 ± 3.0 bMQL bMQL
Norephedrine bMQL bMQL bMQL bMQL bMQL bMQL
Anti-cancer Azathioprine bMQL bMQL bMQL bMQL – bMQL
Methotrexate bMQL bMQL bMQL bMQL bMQL bMQL
Ifosfamide bMQL bMQL bMQL bMQL – bMQL
Tamoxifen bMQL bMQL bMQL bMQL bMQL –
Anaesthetic and
metabolite
Ketamine 242 ± 70.6 269 ± 73.3 266 ± 66.1 259 ± 43.5 15.3 ± 5.7 80.2 ± 55.2
Norketamine 22.1 ± 6.6 29.4 ± 8.1 34.0 ± 7.0 37.9 ± 5.4 4.0 ± 2.4 13.1 ± 9.5
Anti-depressants and
metabolites
Venlafaxine 553 ± 9.4 502 ± 28.9 533 ± 23.4 539 ± 22.2 bMQL 23.6 ± 11.2
Desmethylvenlafaxine 1173 ± 39.2 1181 ± 96.7 1245 ± 64.9 1223 ± 86.2 76.2 ± 38.4 3.5 ± 1.5
Fluoxetine 47.5 ± 6.6 58.0 ± 20.6 61.9 ± 8.0 96.9 ± 27.3 171 ± 28.6 –
Norfluoxetine bMQL bMQL bMQL bMQL 30.0 ± 6.7 –
Sertraline bMQL bMQL bMQL bMQL 688 ± 127 –
Mirtazapine 47.0 ± 3.7 44.4 ± 2.3 40.5 ± 3.1 44.5 ± 0.9 50.9 ± 8.1 35.2 ± 22.9
Citalopram bMQL bMQL bMQL bMQL bMQL bMQL
Desmethylcitalopram 110 ± 6.1 70.3 ± 2.9 101 ± 13.6 118 ± 4.3 300 ± 94.2 bMQL
Anti-epileptic and
metabolites
CBZ 1102 ± 12.8 1061 ± 90.9 1075 ± 59.6 1100 ± 52.4 105 ± 33.2 30.2 ± 4.0
CBZ10,11-epoxide 238 ± 13.3 242 ± 16.3 253 ± 17.0 255 ± 7.9 – 10.0 ± 2.7
10,11-Dihydro-10-hydroxyCBZ bMQL bMQL bMQL bMQL bMQL bMQL
Calcium channel blocker Diltiazem 61.0 ± 3.9 22.6 ± 2.3 25.3 ± 2.8 11.8 ± 3.4 – 4.3 ± 2.7
Hypnotic Temazepam bMQL bMQL bMQL bMQL bMQL bMQL
Anti-psychotic Quetiapine bMQL bMQL bMQL bMQL bMQL bMQL
Veterinary antibiotic Tylosin bMQL bMQL bMQL bMQL – bMQL
Licit stimulants and
metabolites
Nicotine 98.0 ± 19.0 65.9 ± 16.4 22.8 ± 3.4 25.9 ± 11.2 70.4 ± 16.8 bMQL
Caffeine 2866 ± 174.1 1622 ± 236.0 1261 ± 92.4 747.6 ± 125.6 – 11.6 ± 7.9
Cotinine 218 ± 29.1 148 ± 4.6 59.6 ± 5.0 41.0 ± 10.4 21.7 ± 4.3 bMQL
1,7 dimethylxantine bMQL bMQL bMQL bMQL – –
Analgaesics and
metabolites
Morphine 221 ± 22.4 71.6 ± 14.2 23.8 ± 5.4 3.6 ± 0.7 16.4 ± 5.2 bMQL
Dihydromorphine bMQL bMQL bMQL bMQL 17.3 ± 5.1 bMQL
Normorphine bMQL bMQL bMQL bMQL 72.0 ± 21.8 bMQL
Methadone 24.3 ± 2.6 18.0 ± 2.6 23.1 ± 1.6 24.8 ± 1.9 22.6 ± 3.7 8.8 ± 3.7
EDDP 127 ± 16.8 88.0 ± 7.5 109 ± 9.4 111 ± 6.6 98.8 ± 33.4 3.9 ± 1.1
Codeine 794 ± 110.5 516 ± 30.0 284 ± 31.9 181 ± 30.6 16.2 ± 6.6 bMQL
(continued on next page)
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Table 1 (continued)
Micropollutant class Micropollutant Inlet – trickling
filter effluent
(ng L−1)
Final effluent Sludge (μg
kg−1 dry
weight)
P. australis
(μg kg−1 dry
weight)
Steel slag substrate
– 2 months
(ng L−1)
Gravel substrate – 2
months
(ng L−1)
Gravel substrate –
12 months
(ng L−1)
Norcodeine bMQL bMQL bMQL bMQL bMQL bMQL
Dihydrocodeine 287 ± 15.2 246 ± 12.9 177 ± 2.3 94.0 ± 13.1 7.3 ± 4.8 bMQL
Tramadol 1519 ± 42.6 1406 ± 106.7 1450 ± 66.2 1456 ± 71.1 80.6 ± 20.9 64.6 ± 40.4
N-Desmethyltramadol 1092 ± 20.9 959.6 ± 61.1 976.6 ± 117.0 962.8 ± 28.3 89.1 ± 18.5 50.0 ± 42.5
O-Desmethyltramadol 1592 ± 45.1 1355 ± 132.1 1373 ± 65.3 1535 ± 46.0 – bMQL
Stimulants and
metabolites
Amphetamine bMQL bMQL bMQL bMQL bMQL bMQL
Methamphetamine bMQL bMQL bMQL bMQL bMQL bMQL
MDMA 62.5 ± 42.4 58.3 ± 21.7 52.9 ± 22.6 56.1 ± 16.6 4.6 ± 1.1 6.6 ± 4.6
MDA 28.4 ± 9.3 21.3 ± 5.1 15.0 ± 10.1 12.3 ± 8.4 – bMQL
Cocaine 14.0 ± 5.9 1.8 ± 0.9 b1.1 2.5 ± 1.5 1.5 ± 0.6 bMQL
Benzoylecgonine 312 ± 71.7 193 ± 68.4 17.8 ± 5.9 23.1 ± 12.6 0.9 ± 0.7 bMQL
Anhydroecgonine methylester bMQL bMQL bMQL bMQL – bMQL
Cocaethylene 2.3 ± 0.5 1.4 ± 0.5 1.4 ± 0.3 1.6 ± 0.5 0.5 ± 0.2 bMQL
Mephedrone bMQL bMQL bMQL bMQL bMQL bMQL
MDPV bMQL bMQL bMQL bMQL bMQL bMQL
Opioid and metabolite Heroin bMQL bMQL bMQL bMQL bMQL bMQL
6-Acetylmorphine bMQL bMQL bMQL bMQL – bMQL
Key: E1, estrone; E2, 17β-estradiol; EE2, 17α-ethinylestradiol; CBZ, carbamazepine; EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; MDMA, 3,4-
methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine; bMQL, below method quantitation level;−, not determined.
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otic clarithromycin, the calcium channel blocker diltiazem, the antihy-
pertensive lisinopril and the illicit stimulant cocaine. On the other
hand, anti-depressants and their metabolites, and other recalcitrant
compounds including ketamine (anaesthetic), carbamazepine (anti-ep-
ileptic), tramadol (analgesic), diclofenac (NSAID) and MDMA (illicit
stimulant) were poorly removed or increased in concentration. An in-
crease in concentration during biological treatment is attributed to the
biotransformation of metabolites (not measured by the analytical
method) to the parent micropollutant. Removals of some
micropollutants were similar to those observed in the gravel HSSF con-
structedwetlands (2months and 12months operation) (Table 2). How-
ever, it should be noted that to make more substantive comparisons on
the performance of the differently configured wetlands for
micropollutant remediation, more rigorous sampling is required (i.e.,
sampling over longer time periods as well as during different seasons).
Nevertheless, the removals reported are in agreement with previous
studies (Verlicchi and Zambello 2014).
The same 54 micropollutants which were found in receiving waste-
water for treatment were found in HSSF constructed wetland effluent.
As benzophenone-4 was at the highest receiving concentration and
poorly removedduring treatment, it was found in effluent at the highest
concentrations. Average concentrations of benzophenone-4 in effluent
were in the range 3719 to 3858 ng L−1 (Table 1). Other micropollutants
found at concentrations N1000 ng L−1 following treatment were
naproxen, diclofenac, fexofenadine, ranitidine, desmethylvenlafaxine,
carbamazepine, caffeine, tramadol and O-desmethyltramadol.
Of the 54micropollutants detected several are chiral and exist as en-
antiomers. However, there is a paucity of information on the speciation
of chiral drugs during treatment by constructed wetlands. Stereo-selec-
tive degradation has been previously reported for only ibuprofen
(Matamoros et al. 2009; Hijosa-Valsero et al. 2010) and naproxen
(Matamoros et al. 2009). In our study, 9 different chiral micropollutants
were monitored at the enantiomeric level for the first time (MDMA,
MDA,methamphetamine, amphetamine, mephedrone, atenolol, trama-
dol, venlafane and desvenlafaxine). Receiving inlet wastewater (trick-
ling filter effluent) contained chiral micropollutants whose EF ranged
from 0.23 ± 0.03 for MDMA to 0.67 ± 0.01 for tramadol (Table 3).
These are typical of what is observed in the effluent of secondary treat-
ment processes such as trickling filters or activated sludge (Kasprzyk-
Hordern and Baker 2012).
In final effluent of the steel slag constructed wetland no substantial
changes to the EF (in comparison to inlet wastewater) of any studiedmicropollutants was observed. However, stereo-selective changes to
MDMAwere observed for the gravel constructedwetland (2month op-
eration). Here the EF of MDMA in final effluent was 0.11 ± 0.03 (Table
3). In final effluent of the 12 month operated gravel wetland stereo-se-
lective changes were observed for both MDMA and atenolol. The EF of
MDMA was 0.12 ± 0.04 and similar to that of the other gravel con-
structed wetland (Table 3). However, the EF of atenolol in final effluent
was 0.41 ± 0.01 (inlet EF = 0.48 ± 0.02). Despite the EF of atenolol
being significantly different to the 2 month bed (EF = 0.46 ± 0.01)
(ANOVA, p-value b 0.05), the total atenolol concentration (sum of
both enantiomers) in the 2 effluents were not (ANOVA, p-value N
0.05). Concentrations were 64.5 ± 7.4 ng L−1 and 61.1 ± 7.4 ng L−1
for the wetlands operated for 12 and 2 months, respectively (Table 3).
Such an observation is important as stereo-specific toxicity of atenolol
towards aquatic micro-organisms can be observed (De Andrés et al.
2009). This demonstrates that the speciation of chiral micropollutants
should be measured to better understand HSSF constructed wetland
performance for micropollutant removal.
3.2. Behaviour of micropollutants in the presence of the bed substrate
To assess the behaviour of micropollutants in the presence of the
wetland bed substrate, controlled laboratory microcosms (without
plants) were performed. These were prepared to help establish the
role of substrate on micropollutant removal and to identify possible
mechanism(s) of removal. Steel slag was the chosen substrate for
these experiments as it has not been studied previously. 16
micropollutants were present in the grab sample of trickling filter efflu-
ent used to prepare the microcosms (Table S4. Supplementary mate-
rial). Differences observed in the grab sample compared to the 24 h
composites collected in the full-scale study is attributed to the sample
mode and the likely short-term variability in micropollutant
concentration.
For those micropollutants which exhibited removal in microcosm
studies, the range of fate behaviours observed were broadly
encompassed by atenolol, bezafibrate and morphine (see Fig. S4, Sup-
plementary material). Firstly, atenolol was reduced to b1.8 ng L−1 in
all microcosms containing substrate following 26 h of treatment
(starting concentration was 425.5 ± 1.5 ng L−1, see Table S4, Supple-
mentarymaterial). No substantial differences in removalwere observed
between microcosms which were biologically active and those treated
with NaN3, confirming the dominant removal pathway here was by
sorption. As atenolol is present in the cationic form and the biofilm on
Table 2
Removal efficiency (%) of micropollutants by differently configured constructed wetlands receiving the same source of treated wastewater (n= 4).
Micropollutant class Micropollutant HSSF constructed wetland configuration
Steel slag substrate – 2 months
operation
Gravel substrate – 2 months
operation
Gravel substrate – 12 months
operation
UV-filters Benzophenone-1 – – –
Benzophenone-2 – – –
Benzophenone-3 −41 ± 38 31 ± 11 −50 ± 21
Benzophenone-4 8 ± 11 7 ± 3 11 ± 8
Parabens Methylparaben 5 ± 15 16 ± 3 17 ± 11
Ethylparaben – – –
Propylparaben −24 ± 41 1 ± 17 −43 ± 45
Butylparaben – – –
Plasticizer Bisphenol-A 7 ± 30 5 ± 64 3 ± 51
Steroid estrogens E1 36 ± 15 N70 N70
E2 – – –
EE2 – – –
Human
antibiotics/antibacterials
Sulfasalazine 5 ± 5 28 ± 9 51 ± 2
Clarithromycin 73 ± 6 45 ± 3 46 ± 11
Azithromycin – – –
Trimethoprim 24 ± 15 45 ± 5 67 ± 5
Sulfamethoxazole 19 ± 18 28 ± 10 30 ± 4
Triclosan −2 ± 31 19 ± 13 20 ± 12
Antihypertensives Valsartan 18 ± 14 14 ± 7 19 ± 11
Irbesartan 3 ± 7 −5 ± 6 −4 ± 6
Lisinopril 58 ± 22 N71 N71
NSAIDs Ketoprofen – – –
Ibuprofen 27 ± 13 26 ± 8 31 ± 10
Naproxen 23 ± 17 23 ± 7 32 ± 9
Diclofenac 1 ± 44 0 ± 37 −5 ± 54
Acetaminophen 20 ± 80 69 ± 16 51 ± 37
Lipid regulators Bezafibrate 46 ± 4 48 ± 2 61 ± 5
Atorvastatin 32 ± 10 65 ± 7 66 ± 10
Antihistamines Fexofenadine 16 ± 4 40 ± 4 67 ± 3
Cetirizine 6 ± 6 9 ± 5 12 ± 5
Diabetes Gliclazide 21 ± 28 13 ± 20 13 ± 12
Cough suppressant Pholcodine – – –
Beta-blocker Atenolol 69 ± 6 79 ± 3 77 ± 3
Metoprolol −2 ± 41 4 ± 61 22 ± 42
Propranolol 19 ± 6 17 ± 2 30 ± 4
H2 receptor agonists Ranitidine 24 ± 12 33 ± 7 43 ± 6
Cimetidine – – –
X-ray contrast media Iopromide – – –
Drug precursor and metabolite Ephedrine/pseudoephedrine 19 ± 13 58 ± 6 69 ± 4
Norephedrine – – –
Anti-cancer Azathioprine – – –
Methotrexate – – –
Ifosfamide – – –
Tamoxifen – – –
Anaesthetic and metabolite Ketamine −11 ± 2 −11 ± 4 −9 ± 12
Norketamine −34 ± 10 −57 ± 18 −78 ± 35
Anti-depressants and
metabolites
Venlafaxine 9 ± 4 3 ± 6 2 ± 3
Desmethylvenlafaxine −1 ± 6 −6 ± 7 −4 ± 5
Fluoxetine −24 ± 48 −32 ± 23 −112 ± 83
Norfluoxetine – – –
Sertraline – – –
Mirtazapine 5 ± 10 14 ± 8 5 ± 8
Citalopram – – –
Desmethylcitalopram 36 ± 1 8 ± 14 −8 ± 6
Anti-epileptic and metabolites CBZ 4 ± 8 2 ± 5 0 ± 4
CBZ10,11-epoxide −2 ± 12 −6 ± 7 −7 ± 3
10,11-Dihydro-10-hydroxyCBZ – – –
Calcium channel blocker Diltiazem 63 ± 6 59 ± 4 81 ± 6
Hypnotic Temazepam – – –
Anti-psychotic Quetiapine – – –
Veterinary antibiotic Tylosin – – –
Licit stimulants and metabolites Nicotine 33 ± 10 76 ± 4 74 ± 9
Caffeine 43 ± 8 56 ± 1 74 ± 5
Cotinine 31 ± 9 72 ± 2 81 ± 4
1,7 dimethylxantine – – –
Analgaesics and metabolites Morphine 68 ± 5 89 ± 2 98 ± 2
Dihydromorphine – – –
Normorphine – – –
Methadone 26 ± 9 4 ± 5 −3 ± 10
EDDP 30 ± 8 13 ± 6 12 ± 8
Codeine 34 ± 9 64 ± 2 77 ± 5
Norcodeine – – –
(continued on next page)
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Table 2 (continued)
Micropollutant class Micropollutant HSSF constructed wetland configuration
Steel slag substrate – 2 months
operation
Gravel substrate – 2 months
operation
Gravel substrate – 12 months
operation
Dihydrocodeine 14 ± 6 38 ± 3 67 ± 6
Tramadol 7 ± 7 4 ± 6 4 ± 4
N-Desmethyltramadol 12 ± 5 10 ± 11 12 ± 3
O-Desmethyltramadol 15 ± 9 14 ± 5 4 ± 4
Stimulants and metabolites Amphetamine – – –
Methamphetamine – – –
MDMA −15 ± 64 2 ± 40 −14 ± 60
MDA 22 ± 18 51 ± 35 59 ± 32
Cocaine 88 ± 1 N92 81 ± 13
Benzoylecgonine 39 ± 8 94 ± 1 93 ± 4
Anhydroecgonine methylester – – –
Cocaethylene 40 ± 13 38 ± 14 27 ± 21
Mephedrone – – –
MDPV – – –
Opioid and metabolite Heroin – – –
6-Acetylmorphine – – –
Note: –, micropollutant not detected in receiving wastewater.
Key: E1, estrone; E2, 17β-estradiol; EE2, 17α-ethinylestradiol; CBZ, carbamazepine; CBZ 10,11 epoxide, carbamazepine 10,11 epoxide; EDDP, 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine; MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine.
654 B. Petrie et al. / Science of the Total Environment 630 (2018) 648–657the substrate is predominantly negatively charged (Zhang et al. 2014),
electrostatic interactions are suggested as the sorption mechanism re-
sponsible for removal here. Other micropollutants which were found
to be removed by sorption were E1, cocaine, benzoylecgonine and
EDDP (data not shown). However, it must be considered that once equi-
librium is achieved in a continuous process (i.e., the full-scale HSSF con-
structed wetlands), there will be no net removal by sorption unless
accumulation can be demonstrated.
In contrast, notable bezafibrate removals were only found in biotic
microcosm vessels which contained substrate. Here removals of 74.1–
83.6% were observed over 50 h (see Fig. S4, Supplementary material).
No removal was observed in abiotic microcosms or biotic vessels
which did not contain substrate. This demonstrates removal of
bezafibrate was biological in nature and governed by the active biofilm
present on the substrate surface. The beta-blocker propranolol also
showed evidence of being removed by biological degradation as it re-
duced in biotic vessels containing substrate, but not in equivalent abi-
otic vessels.
Finally, morphinewas found to be removed by both sorption and bi-
ological transformation. Abiotic microcosms which contained substrate
showed an initial reduction in morphine concentration of 28.3–33.7%
within the first 4 h (see Fig. S4, Supplementary material). The concen-
tration then remained stable for the rest of the study. This is typical
for sorption as partitioning equilibrium is established almost immedi-
ately (Ternes et al. 2004). In biotic microcosms the concentration of
morphine continued to reduce after 4 h due to biological transforma-
tion. After 26 h the initial concentration was reduced by 80.1–88.1%.Table 3
Concentration and enantiomeric fraction of chiral micropollutants in inlet wastewater (tricklin
Micropollutant class Chiral micropollutant Inlet – trickling filter effluent Steel slag
2 months
Conc. (ng L−1) EF Conc. (ng
Illicit stimulant MDMA 62.5 ± 42.4 0.23 ± 0.03 58.3 ± 21
MDA 28.4 ± 9.3 –a 21.3 ± 5.
Methamphetamine bMQL – bMQL
Amphetamine bMQL – bMQL
Mephedrone bMQL – bMQL
Beta-blocker Atenolol 287 ± 27.6 0.48 ± 0.02 89.1 ± 7.
Analgaesic Tramadol 1519 ± 42.6 0.67 ± 0.01 1406 ± 1
Anti-depressant Venlafaxine 553 ± 9.4 0.56 ± 0.01 502 ± 28
Desvenlafaxine 1173 ± 39.2 0.51 ± 0.00 1181 ± 9
Key: conc., concentration; EF, enantiomeric fraction; MDMA, 3,4-methylenedioxy-methamphe
a bMQL of enantio-selective CBH method.Similar observations were noted for codeine. Little difference in
micropollutant removal was observed for “light” and “dark” micro-
cosms containing substrate under biotic and abiotic conditions (see
Table S4, Supplementary material). This is to be expected as the sub-
strate will shade the exposure of micropollutants to light.
Findings indicated both biological transformation and sorption con-
tributed to micropollutant removal in microcosm studies, and is com-
pound specific. This is in agreement with other researchers which
have discussed the removal pathways of micropollutants in conven-
tional substrates (e.g., gravel) (Ávila et al. 2010; Li et al. 2014). The re-
maining micropollutants (carbamazepine, ibuprofen, naproxen,
cotinine, MDMA, venlafaxine and norketamine – see Table S4, Supple-
mentary material) did not show any notable removals during micro-
cosm studies and their concentrations remained largely unchanged.
Conducting similar studies in the future as the bed (and biofilm) ages
would further our understanding of micropollutant removal in such
systems.
3.3. Micropollutants in HSSF constructed wetland sludge
In the full-scale beds, sludge accumulates over timewhich can act as
a sink for micropollutants. Analysis of sludge collected from the longest
operated wetland found 37 of the studiedmicropollutants to be present
(Table 1). This suggests partitioning into sludge could contribute to
their removal. Those sub-classes with the highest representation in
sludge were anti-depressants and analgaesics. Nevertheless, a broad
representation of micropollutant sub-classes was noted. Tog filter effluent) and final effluent from the studied constructed wetlands.
substrate effluent –
operation
Gravel substrate effluent – 2
months operation
Gravel substrate effluent – 12
months operation
L−1) EF Conc. (ng L−1) EF Conc. (ng L−1) EF
.7 0.20 ± 0.04 52.9 ± 22.6 0.11 ± 0.03 56.1 ± 16.6 0.12 ± 0.04
1 –a 15.0 ± 10.1 –a 12.3 ± 8.4 –a
– bMQL – bMQL –
– bMQL – bMQL –
– bMQL – bMQL –
7 0.47 ± 0.02 61.1 ± 7.4 0.46 ± 0.01 64.5 ± 7.4 0.41 ± 0.01
06.7 0.67 ± 0.01 1450 ± 66.2 0.68 ± 0.01 1456 ± 71.1 0.68 ± 0.01
.9 0.57 ± 0.01 533 ± 23.4 0.57 ± 0.01 539 ± 22.2 0.58 ± 0.01
6.7 0.51 ± 0.01 1245 ± 64.9 0.51 ± 0.01 1223 ± 86.2 0.50 ± 0.01
tamine; MDA, 3,4-methylenedioxy-amphetamine; MQL, method quantitation limit.
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Fig. 1.Mean whole plant concentration of detected micropollutants in P. australis tissues
(n = 8) Key: CBZ, carbamazepine; CBZ 10,11 epoxide, carbamazepine 10,11 epoxide;
EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; MDMA, 3,4-methylene
dioxymethamphetamine.
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methylparaben, bisphenol-A, propranolol, ranitidine, fluoxetine, sertra-
line, demethylcitalopram and carbamazepine. For partitioning into
sludge to be an effective removal pathway, sludge micropolluant levels
(e.g., mg bed−1) need to be high relative to quantity removed from
wastewater (mg d−1). This would indicate accumulation within sludge
over time (as no sludge is removed from the HSSF beds during
operation).
The antidepressant sertraline was found at the greatest levels in
sludge at 688 ± 127 μg kg−1 which equates to 4816 mg bed−1. Sertra-
line was not found in wastewater at quantifiable levels throughout the
sampling campaign (b4.7 mg d−1). This indicates that sludge acts as a
concentrating medium for sertraline. It is also likely that particulate
bound sertraline in receiving wastewater also contributed to the levels
found in sludge. This was not measured due to the low levels of
suspended solids present (~30 mg L−1). Furthermore, both fluoxetine
(1197 mg bed−1) and desmethylcitalopram (2100 mg bed−1) were
found at considerable concentrations in sludge despite showing no net
removal from aqueous wastewater. Antidepressants are well-known
for their partitioning in solid phases of environmental matrices
(Lajeunesse et al., 2012). Both sertraline and fluoxetine are considered
hydrophobic in nature with relatively high log KOW's of 5.29 and 4.65,
respectively.
On the other hand, the estimated quantity of the preservative
methylparaben (log KOW 2.00) present in sludge was 2772 mg bed−1.
Considering the average removal of methylparaben achieved during
treatment (3.4 mg d−1), partitioning into the sludge bed is suggested
to contribute to its overall removal. All other micropollutants that
were found in sludge did not show such great discrepancies between
sludge levels and removals from wastewater. It is postulated that the
distribution of these micropollutants between wastewater and sludge
is under equilibrium, similar to the observations of steroid estrogens
in activated sludge plants (Andersen et al. 2005). As a result there is
no net removal from wastewater by partitioning into sludge.
3.4. Presence of micropollutants in plant tissues of P. australis
It has been proposed that plant presence enhances micropollutant
removal during constructed wetland treatment (Carvalho et al. 2014;
Li et al. 2014; Verlicchi and Zambello 2014). Chen et al. (2015) reported
that the presence of plants and plant litter increased diversity and abun-
dance of bacterial communities in constructed wetlands. Nevertheless,
little is known on the direct role of plants (e.g., uptake andmetabolism)
to micropollutant removal in HSSF constructed wetlands under field
conditions. This is because there has been a lack of micropollutant anal-
ysis undertaken on emergent macrophytes grown in constructed wet-
lands due to the analytical challenges posed (Petrie et al. 2017).
In this study P. australiswere collected and analysed from the gravel
bed which had been operational for 12 months during the monitoring
period to help understand the direct role of plants onmicropollutant re-
moval. A total of 17 micropollutants (12 parent compounds and 5 me-
tabolites) were detected at least once in the studied plants at
concentrations in the μg kg−1 range (Fig. 1). Theseweremethylparaben,
bisphenol-A, propranolol, ketamine and norketamine, venlafaxine and
desmethylvenlafaxine, mirtazapine, carabamazepine and carbamaze-
pine 10, 11 epoxide, diltiazem, caffeine,methadone and EDDP, tramadol
and N-desmethyltramadol, and MDMA (Table 1). Methylparaben was
found at the highest levels up to a maximum concentration of 6.7
μg plant−1 found. All micropollutants found in P. australis were in the
cationic or neutral form in wastewater (pH 8.0) which enables their
movement across the root cell membrane. No negatively charged
micropollutantswere foundwithin P. australis because charge repulsion
with the negatively charged biomembrane of the plant root restricts up-
take (Trapp 2009; Matamoros et al. 2012; Wu et al. 2013).
It has been previously reported that compounds with a log KOW of
between 0.5 and 3.0 can be taken up by plants (Pilon-Smits 2005;Zhang et al. 2014). This enables them to travel through the lipid mem-
brane bilayer whilst being sufficiently water soluble to travel into cell
fluids. They can then be transported within the plant by transpiration.
This explained why micropollutants such as atenolol (log KOW−0.03
and cationic – see Table S1, Supplementary material) were not found
within P. australis. On the other hand, caffeine (log KOW 0.16) was
found within reeds. This is because it was present in the neutral form
at pH 8, suggesting uptake of cationic and neutral species are governed
by different mechanisms.
Process balanceswere used as a qualitativemeasure to help estimate
the role P. australis plays onmicropollutant removal during constructed
wetland treatment. This was done using whole plant concentrations
and accounted for the estimated number of plants within the bed.
These process balances revealed the total quantity of micropollutants
found in P. australis was small in comparison to the daily inlet load
(see Fig. S5; Tables 1 and S5, Supplementary material). For example,
the total quantity of propranolol found in P. australis was estimated to
be 6.6 ± 7.4 mg bed−1 (using an estimated plant density of 10 plants
per m2) in comparison to the receiving load which was 109 ±
10.4mgd−1 (see Fig. S5, Supplementarymaterial). This suggests uptake
by plants does not contribute significantly to total removals. However,
further knowledge of plant metabolism is needed to better appreciate
the direct role plants could play in micropollutant removal.
To better understand metabolism of micropollutants by P. australis
under field conditions, sub-sections of P. australis were investigated
for the presence of micropollutants. The different sections studied
were roots, 4 × 30 cm sections of stem, and leaves. Notable differences
were observed in the behaviour of different micropollutants. The illicit
stimulant MDMA was found at similar concentrations throughout the
plant ranging from 2.2 ± 0.3 μg kg−1 in roots to 5.2 ± 0.1 μg kg−1 in
the first section of stem (Fig. 2). Interestingly the EF of MDMA was
0.25 ± 0.04 in roots which was similar to that of the inlet wastewater
(EF = 0.23 ± 0.03 – Table 2). This demonstrates transport across the
cell membrane was not a stereo-selective process in this instance.
Roots
Stem 1 (30 cm)
Stem 2 (30 cm)
Stem 3 (30 cm)
Leaves
MDMA = 2.2 ±0.3 µg kg-1
EF = 0.25 ±0.04
MDMA = 5.2 ±0.1 µg kg-1
EF = 0.16 ±0.05
MDMA = 4.0 ±0.4 µg kg-1
EF = 0.16 ±0.02
MDMA = 3.9 ±0.1 µg kg-1
EF = 0.16 ±0.02
Stem 4 (30 cm) MDMA = 3.3 ±0.1 µg kg
-1
EF = 0.16 ±0.01
MDMA = 3.8 ±0.4 µg kg-1
EF = 0.20 ±0.04
Ketamine = 10.5 ±6.4 µg kg-1
Norketamine = 1.2 ±0.9 µg kg-1
Ratio = 8.5
Ketamine = 45.3 ±1.1 µg kg-1
Norketamine = 3.1 ±0.4 µg kg-1
Ratio = 14.6
Ketamine = 59.7 ±4.0 µg kg-1
Norketamine = 5.3 ±0.6 µg kg-1
Ratio = 11.3
Ketamine = 69.1 ±6.1 µg kg-1
Norketamine = 6.9 ±0.8 µg kg-1
Ratio = 10.1
Ketamine = 42.0 ±1.5 µg kg-1
Norketamine = 4.0 ±0.2 µg kg-1
Ratio = 10.4
Ketamine = 242 ±12.4 µg kg-1
Norketamine = 33.9 ±7.9 µg kg-1
Ratio = 7.2
CBZ = 26.4 ±10.9 µg kg-1
CBZ 10,11 epoxide = 5.2 ±1.8 µg kg-1
Ratio = 5.1
CBZ = 46.0 ±1.4 µg kg-1
CBZ 10,11 epoxide = 5.5 ±1.1 µg kg-1
Ratio = 8.4
CBZ = 45.2 ±0.2 µg kg-1
CBZ 10,11 epoxide = 5.3 ±0.7 µg kg-1
Ratio = 8.6
CBZ = 37.8 ±1.3 µg kg-1
CBZ 10,11 epoxide = 4.7 ±0.2 µg kg-1
Ratio = 8.0
CBZ = 28.5 ±0.2 µg kg-1
CBZ 10,11 epoxide = 4.2 ±0.5 µg kg-1
Ratio = 6.7
CBZ = 23.8 ±6.0 µg kg-1
CBZ 10,11 epoxide = 14.0 ±1.6 µg kg-1
Ratio = 1.7
(A) (B) (C)
Fig. 2. Concentration of MDMA (A), ketamine and norketamine (B), and carbamazepine and carbamazepine 10,11 epoxide (C) in different plant sections (roots, stem and leaves).
Concentrations of all detected micropollutants are in Table S6. Key: MDMA, 3,4-methylenedioxy-methamphetamine; EF, enantiomeric fraction; CBZ, carbamazepine; CBZ 10,11
epoxide, carbamazepine 10,11 epoxide.
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all sections of stem the EF was 0.16. This can be caused by stereo-selec-
tive metabolism within the plant or by stereo-selective transport be-
tween the roots and the stem. Stereo-selective metabolism of the
chiral pesticide isofenphos-methyl has previously been observed in
the vegetable pak choi (Gao et al. 2016).
Ketamine and its metabolite norketamine were present within the
stem at concentrations ranging from 42.0–69.1 μg kg−1 and 3.1–6.9
μg kg−1, respectively (Fig. 2). However, in leaves the concentration in-
creased to 242 ± 12.4 μg kg−1 and 33.9 ± 7.9 μg kg−1. This accounted
for N50% of the total quantity found in P. australis (See Fig. S6, Supple-
mentary material). Changes were observed to the ratio of ketamine to
norketamine throughout the plant. In the first stem section the ratio
was 14.6 which reduced throughout the plant to 7.2 in leaves (Fig. 2);
suggesting ketamine was transformed to norketamine within the
plant (assuming the rate of translocation within the plant is the same
for ketamine and norketamine). Nevertheless, the rate of uptake and
translocation of ketamine was greater than its rate of transformation
resulting in its accumulation in leaves. A similar relationship was also
observed for methylparaben, tramadol and venlafaxine (see Table S6,
Supplementary material).
Carbamazepine and itsmetabolite carbamazepine 10,11 epoxide be-
haved similarly, although no parent compound accumulation (i.e., no
increased concentration compared to the rest of the plant) was ob-
served in leaves. Wu et al. (2013) has previously reported that carba-
mazepine is easily translocated from the roots of vegetables to their
stems and leaves. In the stem the carbamazepine: carbamazepine
10,11 epoxide ratio ranged from 6.7 to 8.6. In leaves the ratio reduced
to 1.7 due to an increased concentration of the metabolite. Again, this
suggests metabolism of carbamazepine occurs within the plant. Metab-
olism of carbamazepine has been previously reported in vegetables
(Goldstein et al. 2014; Malchi et al. 2014). Furthermore, Lv et al.
(2017) found that the pesticides tebuconazole and imazalil weretaken up from hydroponic water, translocated and degraded simulta-
neously by P. australis. Therefore to apportion the removal of
micropollutants from the constructed wetland by phytoremediation,
further knowledge of uptake and metabolism rates under field condi-
tions are needed. However, it should be noted that there was no net re-
moval of either carbamazepine or ketamine by the constructedwetland
(Table 1), despite evidence of their metabolism. It is postulated that the
rate of uptake and metabolism is too slow to have an impact on the
overall removal of thesemicropollutants at the 14 hHRTwhich the con-
structed wetland operates. Nevertheless, wetland systems are often op-
erated at longer HRTs (i.e., N5 days) which may enable plants to play a
direct role in micropollutant removal.4. Conclusion
The determination of 88 micropollutants in biotic phases of HSSF
constructed wetlands revealed that biodegradation is the dominant
mechanism of micropollutant removal in HSSF constructed wetlands.
Although numerous micropollutants were susceptible to sorption onto
the bed substrate as well as sludge, partitioning between aqueous and
particulate phases is under equilibrium. Therefore the net removal of
these micropollutants by sorption is minimal. Nevertheless, accumula-
tion of the preservative methylparaben and antidepressents sertraline,
fluoxetine and desmethylcitalopram in sludge suggested sorption con-
tributes to their overall removal. Process balances indicated that P.
australis did not directly contribute to micropollutant removal (i.e.,
through uptake and metabolism). However there was evidence of up-
take and metabolism of recalcitrant micropollutants such as carbamaz-
epine and ketamine.
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studied micropollutants (Table S1), method detail (Tables S2–3), mon-
itoring data (Tables S4–7) and additional references. Supplementary
data to this article can be found online at doi:https://doi.org/10.1016/j.
scitotenv.2018.02.242.
References
Andersen, H.R., Hansen, M., Kjølholt, J., Stuer-Lauridsen, F., Ternes, T., Halling-Sørensen, B.,
2005. Assessment of the importance of sorption of steroid estrogens removal during
activated sludge treatment. Chemosphere (1), 139–146.
Ávila, C., Pedescoll, A., Matamoros, V., Bayona, J.M., García, J., 2010. Capacity of a horizontal
subsurface flow constructed wetland system for the removal of emerging pollutants:
an injection experiment. Chemosphere 81 (9), 1137–1142.
Ávila, C., Bayona, J.M., Martín, I., Salas, J.J., García, J., 2015. Emerging organic contaminant
removal in a full-scale hybrid constructed wetland system for wastewater treatment
and reuse. Ecol. Eng. 80, 108–116.
Carvalho, P.N., Basto, M.C.P., Almeida, C.M.R., Brix, H., 2014. A review of plant–pharmaceu-
tical interactions: from uptake and effects in crop plants to phytoremediation in con-
structed wetlands. Environ. Sci. Pollut. Res. 21 (20), 11729–11763.
Castrignanò, E., Lubben, A., Kasprzyk-Hordern, B., 2016. Enantiomeric profiling of chiral
drug biomarkers in wastewater with the usage of chiral liquid chromatography
coupled with tandem mass spectrometry. J. Chromatogr. A 1438, 84–99.
Chen, Y.,Wen, Y., Tang, Z., Huang, J., Zhou, Q., Vymazal, J., 2015. Effects of plant biomass on
bacterial community structure in constructed wetlands used for tertiary wastewater
treatment. Ecol. Eng. 84, 38–45.
De Andrés, F., Castañeda, G., Ríos, A., 2009. Use of toxicity assays for enantiomeric discrim-
ination of pharmaceutical substances. Chirality 21 (8), 751–759.
Gao, B., Zhang, Q., Tian, M., Zhang, Z., Wang, M., 2016. Enantioselective determination of
the chiral pesticide isofenphos-methyl in vegetables, fruits, and soil and its
enantioselective degradation in pak choi using HPLCwith UV detection. Anal. Bioanal.
Chem. 408 (24), 6719–6727.
Ge, Y., Wang, X.C., Dzakpasu, M., Zheng, Y., Zhao, Y., Xiong, J., 2016. Characterizing phos-
phorus removal from polluted urban river water by steel slags in a vertical flow con-
structed wetland. Water Sci. Technol. 73 (11), 2644–2653.
Goldstein, M., Shenker, M., Chefetz, B., 2014. Insights into the uptake processes of waste-
water-borne pharmaceuticals by vegetables. Environ. Sci. Technol. 48 (10),
5593–5600.
He, Y., Langenhoff, A.A.M., Sutton, N.B., Rijnaarts, H.H.M., Blokland, M.H., Chen, F., Huber,
C., Schrӧder, P., 2017. Metabolism of ibuprofen by Phragmites australis: uptake and
phytodegradation. Environ. Sci. Technol. 51 (8), 4576–4584.
Hijosa-Valsero, M., Matamoros, V., Martín-Villacorta, J., Bécares, E., Bayona, J.M., 2010. As-
sessment of full-scale natural systems for the removal of PPCPs from wastewater in
small communities. Water Res. 44 (5), 1429–1439.Kasprzyk-Hordern, B., Baker, D.R., 2012. Enantiomeric profiling of chiral drugs in waste-
water and receiving waters. Environ. Sci. Technol. 46 (3), 1681–1691.
Kyambadde, J., Kansiime, F., Gumaelius, L., Dalhammar, G., 2004. A comparative study of
Cyperus papyrus andMiscanthidium violaceum-based constructedwetlands for waste-
water treatment in a tropical climate. Water Res. 38 (2), 475–485.
Lajeunesse, A., Smyth, S.A., Barclay, K., Sauvé, S., Gagnon, C., 2012. Distribution of antide-
pressant residues in wastewater and biosolids following different treatment pro-
cesses by municipal wastewater treatment plants in Canada. Water Res. 46 (17),
5600–5612.
Li, Y., Zhu, G., Ng, W.J., Tan, S.K., 2014. A review on removing pharmaceutical contami-
nants from wastewater by constructed wetlands: design, performance and mecha-
nism. Sci. Total Environ. 468-469, 908–932.
Lv, T., Carvalho, P.N., Escola Casas, M., Bollmann, U.E., Arias, C.A., Brix, H., Bester, K., 2017.
Enantioselective uptake, translocation and degradation of the chiral pesticides
tebuconazole and imazalil by Phragmites australis. Environ. Pollut. 229, 362–370.
Malchi, T., Maor, Y., Tadmor, G., Shenker, M., Chefetz, B., 2014. Irrigation of root vegetables
with treated wastewater: evaluating uptake of pharmaceuticals and the associated
human health risks. Environ. Sci. Technol. 48 (16), 9325–9333.
Matamoros, V., Hijosa, M., Bayona, J.M., 2009. Assessment of the pharmaceutical active
compounds removal in wastewater treatment systems at enantiomeric level. Ibupro-
fen and naproxen. Chemosphere 75 (2), 200–205.
Matamoros, V., Nguyen, L.X., Arias, C.A., Salvadó, V., Brix, H., 2012. Evaluation of aquatic
plants for removing polar microcontaminants: a microcosm experiment.
Chemosphere 88 (10), 1257–1264.
Matamoros, V., Rodríguez, Y., Albaigés, J., 2016. A comparative assessment of intensive
and extensive wastewater treatment technologies for removing emerging contami-
nants in small communities. Water Res. 88, 777–785.
Park, J.H., Kim, S.H., Delaune, R.D., Kang, B.H., Kang, S.W., Cho, J.S., Ok, Y.S., Seo, D.C., 2016.
Enhancement of phosphorus removal with near-neutral pH utilizing steel and
ferronickel slags for application of constructed wetlands. Ecol. Eng. 95, 612–621.
Petrie, B., Barden, R., Kasprzyk-Hordern, B., 2015. A review on emerging contaminants in
wastewaters and the environment: current knowledge, understudied areas and rec-
ommendations for future monitoring. Water Res. 72, 3–27.
Petrie, B., Youdan, J., Barden, R., Kasprzyk-Hordern, B., 2016. Multi-residue analysis of 90
emerging contaminants in liquid and solid environmental matrices by ultra-high-
performance liquid chromatography tandem mass spectrometry. J. Chromatogr. A
1431, 64–78.
Petrie, B., Smith, B.D., Youdan, J., Barden, R., Kasprzyk-Hordern, B., 2017. Multi-residue de-
termination of micropollutants in Phragmites australis from constructed wetlands
using microwave assisted extraction and ultra-high-performance liquid chromatog-
raphy tandem mass spectrometry. Anal. Chim. Acta 959, 91–101.
Pilon-Smits, E., 2005. Phytoremediation. Annu. Rev. Plant Biol. 56, 15–39.
Stanley, J.K., Ramirez, A.J., Mottaleb, M., Chambliss, C.K., Brooks, B.W., 2006.
Enantiospecific toxicity of the β-blocker propranolol to Daphnia magna and
Pimephales promelas. Environ. Toxicol. Chem. 25 (7), 1780.
Stanley, J.K., Ramirez, A.J., Chambliss, C.K., Brooks, B.W., 2007. Enantiospecific sublethal ef-
fects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate.
Chemosphere 69 (1), 9–16.
Tanner, C.C., 2001. Plants as ecosystem engineers in subsurface-flow treatment wetlands.
Water Sci. Technol. 44, 9–17.
Ternes, T.A., Herrmann, N., Bonerz, M., Knacker, T., Siegrist, H., Joss, A., 2004. A rapid
method to measure the solid–water distribution coefficient (Kd) for pharmaceuticals
and musk fragrances in sewage sludge. Water Res. 38, 4075–4084.
Trapp, S., 2009. Bioaccumulation of polar and ionizable compounds in plants. In: Devillers,
J. (Ed.), Ecotoxicology Modeling. Springer, New York, pp. 299–353.
Verlicchi, P., Zambello, E., 2014. How efficient are constructedwetlands in removing phar-
maceuticals from untreated and treated urban wastewaters? A review. Sci. Total En-
viron. 470–471, 1281–1306.
Wu, X., Ernst, F., Conkle, J.L., Gan, J., 2013. Comparative uptake and translocation of phar-
maceutical and personal care products (PPCPs) by common vegetables. Environ. Int.
60, 15–22.
Zhang, D., Gersberg, R.M., Ng, W.J., Tan, S.K., 2014. Removal of pharmaceuticals and per-
sonal care products in aquatic plant-based systems: a review. Environ. Pollut. 184,
620–639.
